153 related articles for article (PubMed ID: 32810185)
1. EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
Larson KL; Huang B; Chen Q; Tucker T; Schuh M; Arnold SM; Kolesar JM
PLoS One; 2020; 15(8):e0237790. PubMed ID: 32810185
[TBL] [Abstract][Full Text] [Related]
2. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
Enewold L; Thomas A
PLoS One; 2016; 11(6):e0156728. PubMed ID: 27294665
[TBL] [Abstract][Full Text] [Related]
3. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
5. Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.
Palazzo LL; Sheehan DF; Tramontano AC; Kong CY
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):926-934. PubMed ID: 30787053
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
[No Abstract] [Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.
Lynch JA; Berse B; Chun D; Rivera D; Filipski KK; Kulich S; Viernes B; DuVall SL; Kelley MJ
Clin Lung Cancer; 2017 Jul; 18(4):401-409. PubMed ID: 28038980
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Schremser K; Rogowski WH; Adler-Reichel S; Tufman AL; Huber RM; Stollenwerk B
Pharmacoeconomics; 2015 Nov; 33(11):1215-28. PubMed ID: 26081300
[TBL] [Abstract][Full Text] [Related]
10. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.
Shen C; Kehl KL; Zhao B; Simon GR; Zhou S; Giordano SH
Clin Lung Cancer; 2017 Jul; 18(4):e233-e241. PubMed ID: 28024927
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
12. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
13. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
[TBL] [Abstract][Full Text] [Related]
14. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Sequist LV; Joshi VA; Jänne PA; Muzikansky A; Fidias P; Meyerson M; Haber DA; Kucherlapati R; Johnson BE; Lynch TJ
Oncologist; 2007 Jan; 12(1):90-8. PubMed ID: 17285735
[TBL] [Abstract][Full Text] [Related]
15. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
Hess LM; Louder A; Winfree K; Zhu YE; Oton AB; Nair R
J Manag Care Spec Pharm; 2017 Jun; 23(6):643-652. PubMed ID: 28530522
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Inno A; Di Noia V; Martini M; D'Argento E; Di Salvatore M; Arena V; Schinzari G; Orlandi A; Larocca LM; Cassano A; Barone C
Pathol Oncol Res; 2019 Apr; 25(2):513-520. PubMed ID: 29557085
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
